Business Operations:

Sector: Healthcare
Industry: Medical Distribution

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

Revenue projections:

COR is projected to experience a revenue decline compared to last year, a development that often leads to investor caution. The drop could negatively impact the company's bottom line, as lower revenues typically signal reduced profitability, prompting more conservative investment strategies.

Financial Ratios:

currentRatio	0.93500
forwardPE	17.21241
debtToEquity	446.51600
earningsGrowth	0.11900
revenueGrowth	0.05100
grossMargins	0.03961
operatingMargins	0.01415
trailingEps	13.47000
forwardEps	19.75319

Cencora, Inc.'s Forward PE ratio is favorable, meaning the stock price aligns well with earnings and isn't overvalued. This allows room for growth, making it an attractive investment for those seeking potential upside while ensuring the stock is not overpriced.
COR's high debt-to-equity ratio suggests a heavily leveraged capital structure. The company relies on debt to fund operations, which could heighten financial risks, particularly if economic conditions deteriorate or profitability declines.
COR's forward EPS being higher than its trailing EPS signals anticipated growth in profitability for the current financial year. This suggests that COR is on track to improve its earnings, outpacing the previous year's performance and reflecting positive market expectations.

Price projections:

Price projections for Cencora, Inc. have gradually risen over time, signaling increased optimism about the company's future prospects. This steady upward revision reflects growing confidence in Cencora, Inc.'s market potential.

Insider Transactions:

Cencora, Inc. saw 17 transactions in which shares were sold with market price at 326.2452931123621.3 transactions to buy COR occurred, with market price at 270.27332560221356.COR's current price levels are marked by more sells than buys, potentially signaling a price decline. If this trend continues, it may suggest that investors expect the stock to drop further in value.

Recommendation changes over time:

Analysts have maintained a buy bias for COR, which could prompt investors to consider the stock as a viable investment. With this positive outlook, COR is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.